Histone Acetyltransferase Inhibitor IV, CPTH2, HAT Inhibitor IV, Cyclopentylidene-(4-(4ʹ-chlorophenyl)thiazol-2-yl)hydrazone, GCN5 Inhibitor II, N-acetyltransferase 10 Inhibitor I, NAT10 Inhibitor I
A cell-permeable thiazolyl-hydrazone compound that inhibits the acetylation of histone H3 by recombinant human Gcn5 in a substrate-competive manner, while exhibiting little activity against rhGcn5 autoacetylation. Although functional knockout of Gcn5 in Saccharomyces cerevisiae by genetic deletion or by CPTH2 treatment is not detrimental to the survival of the budding yeast, CPTH2 treatment is shown to inhibit the growth of yeast strain genetically deleted of Gcn5, but not strains deleted of Elp3 or Sas2.
A cell-permeable thiazolyl-hydrazone compound that inhibits the acetylation of histone H3 by recombinant human Gcn5 in a substrate-competive manner, while exhibiting little activity against rhGcn5 autoacetylation. Although functional knockout of Gcn5 in Saccharomyces cerevisiae by genetic deletion or by CPTH2 treatment is not detrimental to the survival of the budding yeast, CPTH2 treatment is shown to inhibit the growth of yeast strain genetically deleted of Gcn5, but not strains deleted of Elp3 or Sas2.
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Larrieu, D., et al. 2014. Science, 344, 527. Chimenti, F., et al. 2009. J. Med. Chem.52, 530.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Cancer research communications, 2(6), 402-416 (2023-01-24)
The emergence of treatment resistance significantly reduces the clinical utility of many effective targeted therapies. Although both genetic and epigenetic mechanisms of drug resistance have been reported, whether these mechanisms are stochastically selected in individual tumors or governed by a
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
